The stock of Ultragenyx Pharmaceutical Inc (RARE) has gone down by -1.17% for the week, with a -0.48% drop in the past month and a 6.62% rise in the past quarter. The volatility ratio for the week is 3.27%, and the volatility levels for the past 30 days are 3.03% for RARE. The simple moving average for the past 20 days is -3.54% for RARE’s stock, with a 8.86% simple moving average for the past 200 days.
Is It Worth Investing in Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Right Now?
Company’s 36-month beta value is 0.59.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RARE is 86.21M, and currently, short sellers hold a 3.67% ratio of that floaft. The average trading volume of RARE on November 06, 2024 was 669.94K shares.
RARE) stock’s latest price update
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has experienced a rise in its stock price by 2.19 compared to its previous closing price of 51.06. However, the company has seen a fall of -1.17% in its stock price over the last five trading days. zacks.com reported 2024-11-05 that While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Analysts’ Opinion of RARE
Many brokerage firms have already submitted their reports for RARE stocks, with Goldman repeating the rating for RARE by listing it as a “Buy.” The predicted price for RARE in the upcoming period, according to Goldman is $67 based on the research report published on June 06, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see RARE reach a price target of $77. The rating they have provided for RARE stocks is “Outperform” according to the report published on April 22nd, 2024.
Wells Fargo gave a rating of “Overweight” to RARE, setting the target price at $72 in the report published on December 08th of the previous year.
RARE Trading at -5.96% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.57% of loss for the given period.
Volatility was left at 3.03%, however, over the last 30 days, the volatility rate increased by 3.27%, as shares sank -2.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.54% lower at present.
During the last 5 trading sessions, RARE fell by -1.17%, which changed the moving average for the period of 200-days by +16.92% in comparison to the 20-day moving average, which settled at $54.10. In addition, Ultragenyx Pharmaceutical Inc saw 9.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Horn Howard, who sale 7,465 shares at the price of $52.76 back on Oct 10 ’24. After this action, Horn Howard now owns 92,301 shares of Ultragenyx Pharmaceutical Inc, valued at $393,853 using the latest closing price.
KAKKIS EMIL D, the President & CEO of Ultragenyx Pharmaceutical Inc, sale 20,000 shares at $55.85 during a trade that took place back on Sep 03 ’24, which means that KAKKIS EMIL D is holding 2,223,985 shares at $1,117,000 based on the most recent closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -1.14 for the present operating margin
- 0.83 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc stands at -1.22. The total capital return value is set at -0.41. Equity return is now at value -208.43, with -39.94 for asset returns.
Based on Ultragenyx Pharmaceutical Inc (RARE), the company’s capital structure generated 0.68 points at debt to capital in total, while cash flow to debt ratio is standing at -0.52. The debt to equity ratio resting at 2.08. The interest coverage ratio of the stock is -8.22.
Currently, EBITDA for the company is -516.85 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 10.91. The receivables turnover for the company is 4.44for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.
Conclusion
In a nutshell, Ultragenyx Pharmaceutical Inc (RARE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
